Compare ESP & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | PLX |
|---|---|---|
| Founded | 1928 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.2M | 168.1M |
| IPO Year | N/A | 1998 |
| Metric | ESP | PLX |
|---|---|---|
| Price | $56.50 | $2.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 19.5K | ★ 1.2M |
| Earning Date | 02-11-2026 | 03-16-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ 28.72 | N/A |
| EPS | ★ 3.16 | 0.07 |
| Revenue | $42,600,530.00 | ★ $61,840,000.00 |
| Revenue This Year | $9.16 | $14.29 |
| Revenue Next Year | $5.68 | $16.65 |
| P/E Ratio | ★ $18.43 | $39.52 |
| Revenue Growth | 4.90 | ★ 35.41 |
| 52 Week Low | $24.85 | $1.32 |
| 52 Week High | $58.28 | $3.10 |
| Indicator | ESP | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 65.06 | 85.14 |
| Support Level | $51.89 | $2.03 |
| Resistance Level | $58.28 | $2.11 |
| Average True Range (ATR) | 2.66 | 0.12 |
| MACD | 0.16 | 0.08 |
| Stochastic Oscillator | 81.29 | 93.00 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.